Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Inspired Entertainment Q4 2025 Earnings Call - Interactive Growth Drives Margin Turnaround Toward Mid-40s
Inspired closed 2025 with a clear inflection: digital, led by Interactive, now drives the company and pushed Q4 margin to a record 42% and full-year EBITDA to $111 million. Management is guiding 2026 ...
- Q4 record: EBITDA margin hit 42% in the quarter, full-year 2025 EBITDA margin was 37% with EBITDA of $111 million, slightly ahead of consensus.
- Interactive segment delivered strong Q4 growth: revenue up 53% and EBITDA up 60% year-over-year in the quarter.
- 2026 guidance: company-wide EBITDA $112m-$118m, midpoint $115m, which represents low double-digit growth over 2025 when excluding the Holiday Parks divestiture.
- +12 more takeaways
Stagwell Inc. Q4 2025 Earnings Call - AI pivot, record cash flow, and aggressive buyback set up 2026 growth
Stagwell reported Q4 and full-year 2025 results that management says validate a strategic pivot from acquisition-led scale to product-led growth, centered on AI-enabled marketing platforms. The compan...
- Stagwell reported 6% total revenue growth for 2025, driven by 13% growth in digital transformation and 6% growth in marketing services.
- Management says two-year organic net revenue growth in Q4 exceeded 10%, a sequential improvement of roughly 250 basis points, signaling accelerating organic momentum into 2026.
- 2026 guidance: total net revenue growth 8%-12%, adjusted EBITDA $475M-$525M, adjusted EPS $0.98-$1.12, and free cash flow conversion 50%-60%.
- +12 more takeaways
Legend Biotech Q4 2025 Earnings Call - CARVYKTI Profitable; Scaling to 10,000 Annual Doses and Company Profitability in 2026
Legend closed 2025 on a fast track. CARVYKTI became profitable in 2025, delivered roughly $555 million in net trade sales in Q4, and the company reports more than 10,000 patients treated worldwide. Ma...
- CARVYKTI became a profitable franchise in 2025, driving the company toward company-wide profitability in 2026.
- Legend reported approximately $555 million in CARVYKTI net trade sales in Q4 2025, a 66% year-over-year increase.
- Company revenue for Q4 was $306 million, up 64% year-over-year, with gross margin at 61% and CARVYKTI net product gross margin of 57%.
- +12 more takeaways
Ultralife Corporation Q4 2025 Earnings Call - $110M Backlog and $12.2M Impairment Put Momentum on Notice
Ultralife closed FY2025 with tangible progress and a headline that bruises the numbers. Revenue grew to $48.5 million in Q4 and $191.2 million for the year, driven by batteries and new-product tractio...
- Q4 revenue was $48.5 million, up 10.6% year-over-year; full year 2025 revenue was $191.2 million.
- Management recorded a $12.2 million non-cash intangible asset impairment in Q4, driving an operating loss of $10.6 million and a GAAP net loss of $7.4 million, or $0.45 per share.
- Backlog grew to $110.2 million exiting Q4, up $20 million (22.1%) quarter-over-quarter, and represents roughly 58% of trailing twelve months sales; management expects virtually all backlog to ship in 2026.
- +12 more takeaways
Apyx Medical Fourth Quarter and Full Year 2025 Earnings Call - AYON Launch Powers Record Q4, Guidance Points to 2026 Growth and Cash Through 2027
AYON’s commercial launch turned theory into revenue in Q4. Apyx reported record quarter revenue of $19.2 million, driven by a 38% jump in surgical aesthetics sales to $16.7 million as AYON systems and...
- Q4 2025 total revenue $19.2 million, up 35% year over year from $14.2 million.
- Surgical aesthetics revenue for Q4 was $16.7 million, up 38% YoY, largely driven by AYON system sales and single‑use handpieces.
- AYON was fully launched commercially in September 2025; management says early adopter feedback has exceeded expectations and demand has outpaced internal forecasts across multiple metrics.
- +16 more takeaways
Esperion Therapeutics Q4 2025 Earnings Call - Corstasis Buy and Enbumyst Give Esperion a Fast Track into Heart Failure Care
Esperion closed 2025 with clear commercial momentum and a balance sheet that lets it spend to grow. Q4 product sales and prescriptions rose materially, global partner royalties accelerated, and the co...
- Esperion reported Q4 2025 total revenue of $168.4 million, up 144% year-over-year.
- U.S. net product revenue in Q4 was $43.7 million, a 38% increase versus Q4 2024.
- Retail prescription equivalents grew 34% year-over-year, and unique prescribers for NEXLETOL and NEXLIZET rose nearly 25%.
- +13 more takeaways
ARS Pharmaceuticals Q4 and Full Year 2025 Earnings Call - neffy posts $72.2M first-year U.S. net product revenue, launch limited by refill-driven market structure
ARS closed its first full commercial year with $72.2 million in U.S. net product revenue for neffy, and $84.3 million total revenue. Management framed 2025 as a market-education year, highlighting str...
- U.S. net product revenue for neffy in 2025 was $72.2 million, and total revenue was $84.3 million (includes $9.7M collaboration revenue and $2.4M international supply revenue).
- 2025 was positioned as a launch and education year, with management attributing uneven quarterly growth to the refill-dominant structure of the epinephrine market and electronic prescribing patterns.
- Neffy is the only FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis, and real-world data from the neffy Experience Program showed about 90% of anaphylaxis patients treated effectively with a single dose.
- +11 more takeaways
Yalla Group Limited Q4 2025 Earnings Call - New MENA-focused games, AI and $150M buyback set stage for H2 growth
Yalla closed 2025 with solid topline and a clear strategic pivot toward mid-core and hardcore gaming in the Middle East, supported by a hefty balance sheet and an enlarged buyback. Q4 revenue was $83....
- Q4 2025 revenue was $83.9 million; full-year 2025 revenue was $341.9 million, with CEO reporting full-year net income of $148.1 million (up ~10.4%).
- Q4 net income was $34.5 million, up 6.2% year-over-year; non-GAAP Q4 net income was $36.9 million, up 3.2% YoY.
- Monthly active users reached 44.8 million in Q4, up 8.2% year-over-year, signaling continued audience growth across Yalla’s social and gaming ecosystem.
- +11 more takeaways
Vail Resorts Fiscal Second Quarter 2026 Earnings Call - Unprecedented Rockies Drought Trims Guidance, Pass Program Holds the Fort
Vail Resorts cut full-year earnings after the Rockies suffered the worst winter on record for the company, with snowfall and snowpack well below even 2012 levels. The weather-driven hit pushed Q2 net ...
- Rockies weather was the defining factor this season, with snowfall and snowpack near historic lows, described as worse than fiscal 2012.
- Q2 total net revenue fell approximately 5% year-over-year, while Q2 Resort Reported EBITDA declined about 8%.
- Season-to-date skier visitation dropped roughly 12%, with Q2 visitation down ~13%; lift revenue was down ~3%-4% in Q2 and season-to-date.
- +15 more takeaways
Zevra Therapeutics Q4 2025 Earnings Call - MIPLYFFA launch drives revenue, turning company profitable and funding international expansion
Zevra closed 2025 with tangible commercial momentum. MIPLYFFA sales powered $106.5 million of full-year net revenue and a swing to net income, while early international expanded access rollouts and an...
- MIPLYFFA commercial launch is the company story: 2025 net revenue was $106.5 million, with $87.4 million attributable to MIPLYFFA and $26.4 million of MIPLYFFA sales in Q4 alone.
- Zevra turned profitable in 2025, reporting net income of $83.2 million for the full year and $12.2 million in Q4, a sharp reversal from a 2024 net loss of $105.5 million.
- Prescription enrollment momentum: 52 prescription enrollment forms in 2025, including 24 in Q4, and 161 total enrollments since launch, giving management confidence in U.S. uptake.
- +13 more takeaways